Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab
12/12 18:55
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) Monday announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treate...